← SynDRA
ELAGOLIX
SynDRA canonical compound SYN0023682 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | GNRH1 | GNRHR |
|---|
| Mechanism of action | gonadotropin releasing factor hormone receptor antagonist |
|---|
All known targets
Mechanisms of action (all sources)
- GNRHR ANTAGONIST
- Gonadotropin-releasing hormone receptor antagonist
- gonadotropin releasing factor hormone receptor antagonist
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- GPR119
- GLP1R
- ADRB2
- OPRK1
- FFAR4
- APLNR
- CX3CR1
- MBD4
- HTR1B
- HTR1E
- HTR2A
- HTR2B
- HTR2C
- HTR5A
- HTR6
- HTR7
- MPG
- HRH1
- MUTYH
- NEIL1
- NEIL2
- OGG1
- OPRD1
- OPRM1
- S1PR1
- SIGMAR1
- TDG
- HTR1A
- ADGRF1
- HDAC6
- GPR35
- ADRA1D
- ADRA2A
- ADRA2B
- ADRA2C
- ADRB3
- AGTR1
- C5AR1
- CHRM1
- CHRM2
Drug classes
- Gonadotropin Releasing Hormone Receptor Antagonists
- Gonadotropin Releasing Hormone Receptor Antagonist
- Cytochrome P450 2C19 Inhibitors
- P-Glycoprotein Inhibitors
- Cytochrome P450 3A Inducers
ATC classes
- H01C · HYPOTHALAMIC HORMONES
Cross-references
Synonyms
- ORIAHNN (COPACKAGED)
- ORILISSA
- Orilissa
- elagolix sodium
- orilissa
- NBI-56418
- BT-620
- UNII-5B2546MB5Z
- NBI 56418
- 5B2546MB5Z
- NBI56418
- Elagolix [USAN:INN]
- ELA gOLIX
- Elagolix (USAN/INN)
- SCHEMBL1642523
- GTPL8362
- CHEMBL1208155
- DTXSID40232348
- ABT-620
- EX-A1765
- BCP08827
- ZINC49888891
- CS-5329
- SB16700
- DB11979
- compound 10b [PMID 19006286]
- HY-14789
- AN-27202
- D09335
- Z-3253
- 153E876
- Butanoic acid, 4-(((1R)-2-(5-(2-flu
- elagolixum
- RefChem:58959
- DTXCID40154839
- H01CC03
- (R)-Elagolix
- Elagolix [USAN]
Reported adverse events
- Headache
- Suicidal ideation
- Alopecia
- Anxiety
- Arthralgia
- Completed suicide
- Depressed mood
- Depression
- Fatigue
- Hypersensitivity
- Insomnia
- Mood altered
Look up ELAGOLIX in the interactive SynDRA portal →